Cargando…
The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms
We previously reported the CINSARC signature as a prognostic marker for metastatic events in soft tissue sarcomas, breast carcinomas and lymphomas through genomic instability, acting as a major factor for tumor aggressiveness. In this study, we used a published resource to investigate CINSARC enrich...
Autores principales: | Lesluyes, Tom, Delespaul, Lucile, Coindre, Jean-Michel, Chibon, Frédéric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511191/ https://www.ncbi.nlm.nih.gov/pubmed/28710396 http://dx.doi.org/10.1038/s41598-017-05726-x |
Ejemplares similares
-
CINSARC in high‐risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG‐STS 1001 study
por: Frezza, Anna Maria, et al.
Publicado: (2022) -
Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022) -
The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
por: Goncalves, Anthony, et al.
Publicado: (2021) -
Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial
por: Filleron, Thomas, et al.
Publicado: (2020) -
Tetraploidization of Immortalized Myoblasts Induced by Cell Fusion Drives Myogenic Sarcoma Development with DMD Deletion
por: Merle, Candice, et al.
Publicado: (2020)